| Scientific Session I Chairs: R. Rizzoli - E. McCloskey
| |
| Plenary Lecture 1 Osteoporosis and burden of diseases (N. Freemantle)
| |
| Presentation of the ESCEO-Amgen Fellowship Awards | |
| Remittance of the ESCEO Young Investigator Awards supported by a grant from MSD | |
| Oral Communications 09.50-10.00 OC1
The burden of fractures in France, Germany, Italy, Spain, Sweden and the UK - O. Ström, F. Borgström, J.A. Kanis, B. Jönsson
10.00-10.10 OC2
Bone microarchitecture assesment by high-resolution peripheral quantitative computed tomography (HR-pQCT) in healthy women - M. Zanchetta, C. Monteverde, F. Silveira, V. Ripero, C. Bogado, J. Zanchetta
10.10-10.20 OC3
DAPS (Denosumab Adherence Preference Satisfaction): results of the second year of the crossover study - N. Freemantle, D. Kendler, P. Kaur, S. Siddhanti, E. Tang, D. Macarios, S. Satram-Hoang, J. Borenstein, M. McClung
| |
| Plenary Lecture 2 Non invasive evaluation of bone strength (R. Müller)
| |
| Oral Communications 10.50-11.00 OC4
Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis - A. Moayyeri, J. Adams, R. Adler, G. Blake, M-A. Krieg, D. Hans, J. Compston, E.M. Lewiecki
11.00-11.10 OC5
Force directions for optimal proximal femoral strength and hip fracture risk assessment in men and women: the AGES- Reykjavik study - J. Keyak, B. Jonsson, K. Siggeirsdottir, G. Eiriksdottir, V. Gudnason, T. Lang, S. Sigurdsson, G. Karlsdottir, D. Oskarsdottir, A. Sigmarsdottir, S. Zhao, J. Kornak, T. Harris, G. Sigurdsson
11.10-11.20 OC6
Local topological analysis at the distal radius by HR-pQCT: application to in vivo bone microarchitecture and fracture assessment in the OFELY study - J-B. Pialat, N. Vilayphiou, S. Boutroy, P-J. Gouttenoire, E. Sornay-Rendu, R. Chapurlat, F. Peyrin
11.20-11.30 OC7
Clinical risk factors, bone mineral density and falls history in the prediction of incident fracture among men and women - M. Edwards, K. Jameson, H. Denison, A.A. Sayer, C. Cooper, E. Dennison
11.30-11.40 OC8
Risedronate reduces cortical structural decay during menopause, probably by reducing intracortical porosity - E. Seeman, R. Chapurlat, D. Felsenberg, R. Rizzoli
11.40-11.50 OC9
Effects of the cathepsin K inhibitor, ONO-5334, on BMD as measured by 3D QCT in the hip and the spine after 12 months treatment - K. Engelke, S. Nagase, T. Fuerst, R. Eastell, H.K. Genant, M. Small, T. Kuwayama, S. Deacon
| |
| Lunch Symposium - Rottapharm | Madaus Biological plausibility and clinical relevance of the of the medical management of knee osteoarthritis with crystalline glucosamine sulfate - Chairmen: E. Maheu & J.-Y. Reginster
| |
| Lunch Symposium - Pfizer The Evolving Role of SERMS: Changing Perspectives in the Clinical Management of Postmenopausal Osteoporosis - Chairman: S. Palacios
| |
| Poster Session I (P101 to P399) & Exhibition Viewing | |
| ESCEO-FROMO Symposium Long-term treatment of osteoporosis (Chairmen: R. Rizzoli and C. Cooper)
- Welcome - J.-Y. Reginster
- Long-term treatment with calcium and vitamin D - R. Rizzoli
- Long-term treatment with selective estrogen receptor modulators - M. Diaz Curiel
- Long-term treatment with bisphosphonates - R. Lorenc
- Long-term treatment with strontium ranelate - B. Cortet
- Discussion - S. Epstein, J.-Y. Reginster
| |
| Meet the Professor Sessions - Treatment strategy: how long to treat (J.P. Bilezikian, MTP room 1 - 1st floor)
- Guidelines for the management of osteoarthritis (O. Bruyère, MTP room 2 - 1st floor)
- Vitamin D: when and how much? (B. Dawson-Hughes, MTP room 3 - 1st floor)
- Update on renal osteodystrophy (P. Miller, MTP room 4 - 1st floor) canceled
| |
| ESCEO-FROMO Symposium How should partial adherence be taken into account in health economic models in osteoporosis? (Chairmen: J.A. Kanis - M. Hiligsmann)
- Welcome and introduction - J-Y. Reginster
- Basing adherence on empirical observations and how does partial adherence impact on anti-fracture efficacy - M. Hiligsmann and V. Rabenda
- Impact of adherence on health economic assessment in post-menopausal osteoporosis - J. Kanis
- Discussion - J.A. Kanis, S. Corcaud, V. Rabenda, E. Badamgarav, M. Hiligsmann, S. Korte, W. Dere, B. Mitlak, P. Alegre, J-Y. Reginster
| |
| Educational Lecture How to monitor anti-osteoporosis treatments at the individual level ? (S. Papapoulos)
| |
| Oral Presentation of Selected Posters Moderator: E. Seeman
14.15-14.20 P101
Systematic follow up of fragility fracture: preliminary results of a multidisciplinary approach J. Delisle, J. Fernandes, Y. Troyanov, S. Perreault
14.20-14.25 P134
Improvement in muscle power, muscle function and back pain in elderly GIOP patients by combined therapy with alfacalcidol and alendronate J. Ringe, E. Schacht, L.t Dukas, Z. Mazor
14.25-14.30 P159
Does birthweight predict bone mass in adulthood? A systematic review and meta-analysis J. Baird, M. Asim Kurshid, M. Kim, N. Harvey, E. Dennison, C. Cooper
14.30-14.35 P214
Effect of once-yearly zoledronic acid in men after recent hip fracture: results from horizon recurrent fracture trial S. Boonen, J-M. Kaufmann, E. Orwoll, J. Magaziner, C. Colon-Emeric, R. Adachi, C. Bucci-Rechtweg, P. Haentjhens, D. Vanderschueren, K. Lyles
14.35-14.40 P553
Consumption of fermented milk containing blueberry, enriched with calcium and vitamin D positively modulates bone metabolism in postmenopausal women C. Puel, M-J. Davicco, P. Lebecque, V. Coxam
14.40-14.45 P257
Obesity and fractures: a population-based study using the SIDIAP database D. Prieto-Alhambra, F. Fina Aviles, E. Hermosilla, A. Pages-Castella, R. Guerri, X. Nogues, A. Diez-Perez
|
| Scientific Session II Chairs: H. Orimo - J-P. Bilezikian
| |
| Plenary Lecture 3 Pathophysiological basis of osteonecrosis of the jaw and atypical fractures (J. Compston)
| |
| Oral Communications 15.30-15.40 OC10
Incidence and demography of femur fractures with and without atypical features in the Pacific Northwest (NW) United States of America (USA) - A. Feldstein, M. Rix, E. Orwoll, D. Black, N. Perrin, A. Rosales, D. Friess, D. Boardman, R. Dell, A.Santora, J. Chandler
15.40-15.50 OC11
Bisphosphonate use is associated with reduced revisions of lower limb joint (knee or hip) arthroplasty: a population-based cohort study - D. Prieto-Alhambra, M.K. Javaid, A. Judge, D.W. Murray, A.J. Carr, C. Cooper, N.K. Arden
15.50-16.00 OC12
Superior effects of strontium ranelate compared to alendronate on bone mass and strength parameters at the tibia in women with post menopausal osteoporosis - D. Felsenberg, M.L. Brandi, G. Sergi, I. Bergström, G. Beller, C. Fiore, G. Lyritis, A. Kindmark, H. Boerst, O. Bock, M. Hartard, M. Runge
16.00-16.10 OC13
Hemiarthroplasty cost effective in the treatment of femoral neck fractures in the elderly: a cost utility analysis of 2 years of hemiarthroplasty and internal fixation of displaced femoral neck fractures in 166 patients - F. Frihagen, G. Waaler, J.E. Madsen, L. Nordsletten, E. Aas
16.10-16.20 OC14
Quality of life four months following a fracture. Results from the ICUROS - F. Borgström, K.Sanders, T. Thomas, I. Lekander, O. Ström, V. Alekna, M.L. Bianchi, P. Clark, M. Díaz Curiel, H.P. Dimai, O. Lesnyak
16.20-16.30 OC15
Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX® - E. McCloskey, M. Lewiecki, J.A. Kanis, H. Johansson, A. Oden, M. Austin, E. Siris, A. Wang, C. Libanati, R. Chapurlat, R. Lorenc
16.30-16.40 OC16
Bone formation is significantly greater in women on strontium ranelate than in those on alendronate after 6 and 12 months of treatment: histomorphometric analysis from a large randomized controlled trial - P. Chavassieux, K. Brixen, C. Zerbini, R. Pereira, P. De La Peña, I. Valter, T. Hala, P. Novosad, J. Zanchetta, Z. Man, L.G. Ste-Marie, P.J. Meunier, R. Chapurlat
| |
| Satellite Symposium - MSD Emerging concepts in the management of osteoporosis: optimizing patient care - Chairman: A. Diez-Perez
| |
| Satellite Symposium - Servier Healthy bone: a question of structure - Chairmen: J. Cannata, R. Rizzoli
| |
